1. Type of current or former antihypertensive medication:

| Medication Type | Duration of Use (months) | Age at Start (years) | Age at End (years) |
| --- | --- | --- | --- |
| Thiazide diuretics |  |  |  |
| Calcium channel blockers |  |  |  |
| ACE inhibitors |  |  |  |
| Angiotensin II receptors blockers |  |  |  |
| β-blockers |  |  |  |
| α-blockers |  |  |  |
| Other, specify: |  |  |  |

1. Type of antiplatelets received:

| Antiplatelet Type | Duration of Use (months) | Age at Start (years) | Age at End (years) |
| --- | --- | --- | --- |
| Aspirin |  |  |  |
| Aspirin/Dipyridamole (in separate formulations or as Aggrenox) |  |  |  |
| Clopidogrel |  |  |  |
| Ticlopidine  |  |  |  |
| Other, specify: |  |  |  |

1. \*\*\*Type of current or former statin used:

Duration of use (months):

Age when use started (years):

Age when use ended (years):

1. \*\*\*Birth control method(s):

| Method Used | Duration of Use (months) | Age at Start (years) | Age at End (years) |
| --- | --- | --- | --- |
| Abstinence |  |  |  |
| Oral contraceptives – combined pill |  |  |  |
| Oral contraceptives – progestin-only pill |  |  |  |
| Transdermal patch |  |  |  |
| Shot/injection |  |  |  |
| Hormonal (e.g., oral, implanted, injected) |  |  |  |
| None of these |  |  |  |
| Other, specify: |  |  |  |

1. \*\*\*Type of current or former non-steroidal anti-inflammatory drugs (NSAIDs) used:

Duration of use (months):

Age when use started (years):

Age when use ended (years):

1. \*\*\*Type of current or former hormone therapy used:

Duration of use (months):

Age when use started (years):

Age when use ended (years):

1. Type(s) of anticoagulants received:

| Anticoagulant Type | Duration of Use (months) | Age at Start (years) | Age at End (years) |
| --- | --- | --- | --- |
| Unfractionated heparin IV |  |  |  |
| Full dose LMW heparin |  |  |  |
| Warfarin |  |  |  |
| Phenprocoumon |  |  |  |
| Acenocumarol |  |  |  |
| Dabigatran |  |  |  |
| Fondaparinux |  |  |  |
| Rivaroxaban |  |  |  |
| Apixaban |  |  |  |
| Edoxaban |  |  |  |
| Other, specify: |  |  |  |

1. Type of current or former stimulants:

| Substance Type | Duration of Use (months) | Age at Start (years) | Age at End (years) |
| --- | --- | --- | --- |
| Amphetamine derivatives |  |  |  |
| Caffeine (Xanthine derivative) |  |  |  |
| Theophyllin (Xanthine derivative) |  |  |  |
| Theobromin (Xanthine derivative) |  |  |  |
| Others, specify: |  |  |  |

Cocaine: Exposure to cocaine within one year of clinical presentation:

[ ]  Yes

[ ]  No

If yes:

Duration of use (months):

Age when use started (years):

Age when use ended (years):

1. \*\*\*Type of potency-enhancing drug used:

Duration of use (months):

Age when use started (years):

Age when use ended (years):

1. \*\*\*Type of immunosuppressant used:

| Immunosuppressant  | Duration of Use (months) | Age at Start (years) | Age at End (years) |
| --- | --- | --- | --- |
| Corticosteroids systemic |  |  |  |
| Corticosteroids local |  |  |  |
| Other, specify: |  |  |  |

## General Instructions

This CRF contains data on the concomitant medications for UIA studies.

Important note: Some data elements included on this CRF Module are considered Exploratory as specified by asterisks below:

\*\*\*Element is classified as Exploratory

An element not marked by an asterisk is Supplemental and should only be collected if the research team considers it appropriate for the study.

## Specific Instructions

Please see the Data Dictionary for definitions for each of the data elements included in this CRF Module.

* Cocaine use: Exposure of cocaine within one year of clinical presentation